The FDA announced Breakthrough Therapy Designation (BTD) for acalabrutinib (Calquence) as a single agent to treat chronic lymphocytic leukemia (CLL)
It is tough enough to have chronic lymphocytic leukemia (CLL), but for those of us on Medicare, the cost of some treatments can be prohibitive.
Organizations such as LLS and PAN (Patient Access Network) offer help through industry-funded pools of financial aid for those who qualify.
Here is a little early holiday gift for some of our readers.
The exciting and timely news that we have confirmed is that the PAN CLL financial assistance fund is finally reopening on Monday, Nov. 28, 2016. We know it because PAN has chosen the CLL Society to be their partner for offering peer-to-peer CLL counseling. We have been working hard to train volunteers and to develop the policies and procedures needed to protect your privacy and offer robust help. The CLL Society is very proud to partner with PAN.
You can apply for assistance two ways.
Apply over the phone at 1-866-316-7263 Monday through Friday, 9 a.m. to 5 p.m. EST
OR
Visit the patient portal
So seize this early holiday gift while you still can and please tell everyone to join our community and sign up for our alerts and newsletters.
Thank you for being part of the CLL Society. Unlike other web sites, we don’t require visitors to register to gain access to our material, but honestly the number of subscribers is a metric that our supporters assess when considering our grant applications. Without significant grant support, we can’t possibly do everything that patients request. If you like what we are doing, please sign up if you haven’t already and please spread the word and ask other friends to subscribe to our alerts and newsletters here: https://cllsociety.org/newsletter-sign-up/ . It really helps.
You tell us that the news, services, and updates we share are important, relevant and helpful and we want to do even more. We can and will do so with your help.
Brian Koffman, MD 11/28/16
Related posts
